nach oben

Cancer Microenvironment

Erschienen in:

01.12.2015 | Original Paper

The Role of Mast Cells in Molding the Tumor Microenvironment

verfasst von: A. Rigoni, M. P. Colombo, C. Pucillo

Erschienen in: Cancer Microenvironment | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Abstract

Mast cells (MCs) are granulocytic immune cells that reside in tissues exposed to the external environment. MCs are best known for their activity in allergic reactions, but they have been involved in different physiological and pathological conditions. In particular, MC infiltration has been shown in several types of human tumors and in animal cancer models. Nevertheless, the role of MCs in the tumor microenvironment is still debated because they have been associated either to good or poor prognosis depending on tumor type and tissue localization. This dichotomous role relies on MC capacity to secrete a broad spectrum of molecules with modulatory functions, which may condition the final tumor outcome also promoting angiogenesis and tissue remodeling. In this review, we analyze the multifaceted role of mast cell in tumor progression and inhibition considering their ability to interact with: i) immune cells, ii) tumor cells and iii) the extracellular matrix. Eventually, the current MC targeting strategies to treat cancer patients are discussed. Deciphering the actual role of MCs in tumor onset and progression is crucial to identify MC-targeted treatments aimed at killing cancer cells or at making the tumor vulnerable to selected anti-cancer drugs.

Erlich P (1878) Beiträge zur Theorie und Praxis der histologischen Färbung. Dissertation, Leipzig University.

Westphal E (1891) Uber mastzellen. Hirschwald Press, Berlin

Lachter J, Stein M, Lichtig C, Eidelman S, Munichor M (1995) Mast cells in colorectal neoplasias and premalignant disorders. Dis Colon Rectum 38(3):290–293PubMedCrossRef

Ch’ng S, Sullivan M, Yuan L, Davis P, Tan ST (2006) Mast cells dysregulate apoptotic and cell cycle genes in mucosal squamous cell carcinoma. Cancer Cell Int 6:28. doi:10.1186/1475-2867-6-28 PubMedPubMedCentralCrossRef

Amini RM, Aaltonen K, Nevanlinna H, Carvalho R, Salonen L, Heikkila P, Blomqvist C (2007) Mast cells and eosinophils in invasive breast carcinoma. BMC Cancer 7:165. doi:10.1186/1471-2407-7-165 PubMedPubMedCentralCrossRef

Blank U, Falcone FH, Nilsson G (2013) The history of mast cell and basophil research—some lessons learnt from the last century. Allergy 68(9):1093–1101. doi:10.1111/all.12197 PubMed

Tsai M, Grimbaldeston M, Galli SJ (2011) Mast cells and immunoregulation/immunomodulation. Adv Exp Med Biol 716:186–211. doi:10.1007/978-1-4419-9533-9_11 PubMedCrossRef

Metz M, Grimbaldeston MA, Nakae S, Piliponsky AM, Tsai M, Galli SJ (2007) Mast cells in the promotion and limitation of chronic inflammation. Immunol Rev 217:304–328. doi:10.1111/j.1600-065X.2007.00520.x PubMedCrossRef

Kalesnikoff J, Galli SJ (2008) New developments in mast cell biology. Nat Immunol 9(11):1215–1223. doi:10.1038/ni.f.216 PubMedPubMedCentralCrossRef

10.

Gurish MF, Austen KF (2012) Developmental origin and functional specialization of mast cell subsets. Immunity 37(1):25–33. doi:10.1016/j.immuni.2012.07.003 PubMedCrossRef

11.

Anderson DM, Lyman SD, Baird A, Wignall JM, Eisenman J, Rauch C, March CJ, Boswell HS, Gimpel SD, Cosman D et al (1990) Molecular cloning of mast cell growth factor, a hematopoietin that is active in both membrane bound and soluble forms. Cell 63(1):235–243PubMedCrossRef

12.

Meininger CJ, Yano H, Rottapel R, Bernstein A, Zsebo KM, Zetter BR (1992) The c-kit receptor ligand functions as a mast cell chemoattractant. Blood 79(4):958–963PubMed

13.

Ulivi P, Zoli W, Medri L, Amadori D, Saragoni L, Barbanti F, Calistri D, Silvestrini R (2004) c-kit and SCF expression in normal and tumor breast tissue. Breast Cancer Res Treat 83(1):33–42. doi:10.1023/B:BREA.0000010694.35023.9e PubMedCrossRef

14.

Huang B, Lei Z, Zhang GM, Li D, Song C, Li B, Liu Y, Yuan Y, Unkeless J, Xiong H, Feng ZH (2008) SCF-mediated mast cell infiltration and activation exacerbate the inflammation and immunosuppression in tumor microenvironment. Blood 112(4):1269–1279. doi:10.1182/blood-2008-03-147033 PubMedPubMedCentralCrossRef

15.

Pittoni P, Tripodo C, Piconese S, Mauri G, Parenza M, Rigoni A, Sangaletti S, Colombo MP (2011) Mast cell targeting hampers prostate adenocarcinoma development but promotes the occurrence of highly malignant neuroendocrine cancers. Cancer Res 71(18):5987–5997. doi:10.1158/0008-5472.CAN-11-1637 PubMedCrossRef

16.

Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO, Cunha GR, Donjacour AA, Matusik RJ, Rosen JM (1995) Prostate cancer in a transgenic mouse. Proc Natl Acad Sci U S A 92(8):3439–3443PubMedPubMedCentralCrossRef

17.

Pittoni P, Colombo MP (2012) The dark side of mast cell-targeted therapy in prostate cancer. Cancer Res 72(4):831–835. doi:10.1158/0008-5472.CAN-11-3110 PubMedCrossRef

18.

Irani AA, Schechter NM, Craig SS, DeBlois G, Schwartz LB (1986) Two types of human mast cells that have distinct neutral protease compositions. Proc Natl Acad Sci U S A 83(12):4464–4468PubMedPubMedCentralCrossRef

19.

Stone KD, Prussin C, Metcalfe DD (2010) IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol 125(2 Suppl 2):S73–S80. doi:10.1016/j.jaci.2009.11.017 PubMedPubMedCentralCrossRef

20.

Theoharides TC, Conti P (2004) Mast cells: the Jekyll and Hyde of tumor growth. Trends Immunol 25(5):235–241. doi:10.1016/j.it.2004.02.013 PubMedCrossRef

21.

Mori A, Zhai YL, Toki T, Nikaido T, Fujii S (1997) Distribution and heterogeneity of mast cells in the human uterus. Hum Reprod 12(2):368–372PubMedCrossRef

22.

Gelfand EW (2004) Inflammatory mediators in allergic rhinitis. J Allergy Clin Immunol 114(5 Suppl):S135–S138. doi:10.1016/j.jaci.2004.08.043 PubMedCrossRef

23.

Bischoff SC (2009) Physiological and pathophysiological functions of intestinal mast cells. Semin Immunopathol 31(2):185–205. doi:10.1007/s00281-009-0165-4 PubMedCrossRef

24.

Rivera J, Gilfillan AM (2006) Molecular regulation of mast cell activation. J Allergy Clin Immunol 117(6):1214–1225. doi:10.1016/j.jaci.2006.04.015, quiz 1226PubMedCrossRef

25.

Migalovich-Sheikhet H, Friedman S, Mankuta D, Levi-Schaffer F (2012) Novel identified receptors on mast cells. Front Immunol 3:238. doi:10.3389/fimmu.2012.00238 PubMedPubMedCentralCrossRef

26.

Karra L, Levi-Schaffer F (2011) Down-regulation of mast cell responses through ITIM containing inhibitory receptors. Adv Exp Med Biol 716:143–159. doi:10.1007/978-1-4419-9533-9_9 PubMedCrossRef

27.

Gu YZ, Hogenesch JB, Bradfield CA (2000) The PAS superfamily: sensors of environmental and developmental signals. Annu Rev Pharmacol Toxicol 40:519–561. doi:10.1146/annurev.pharmtox.40.1.519 PubMedCrossRef

28.

Matsumoto Y, Ide F, Kishi R, Akutagawa T, Sakai S, Nakamura M, Ishikawa T, Fujii-Kuriyama Y, Nakatsuru Y (2007) Aryl hydrocarbon receptor plays a significant role in mediating airborne particulate-induced carcinogenesis in mice. Environ Sci Technol 41(10):3775–3780PubMedCrossRef

29.

Lin P, Chang H, Ho WL, Wu MH, Su JM (2003) Association of aryl hydrocarbon receptor and cytochrome P4501B1 expressions in human non-small cell lung cancers. Lung Cancer 42(3):255–261PubMedCrossRef

30.

Andersson P, McGuire J, Rubio C, Gradin K, Whitelaw ML, Pettersson S, Hanberg A, Poellinger L (2002) A constitutively active dioxin/aryl hydrocarbon receptor induces stomach tumors. Proc Natl Acad Sci U S A 99(15):9990–9995. doi:10.1073/pnas.152706299 PubMedPubMedCentralCrossRef

31.

Moennikes O, Loeppen S, Buchmann A, Andersson P, Ittrich C, Poellinger L, Schwarz M (2004) A constitutively active dioxin/aryl hydrocarbon receptor promotes hepatocarcinogenesis in mice. Cancer Res 64(14):4707–4710. doi:10.1158/0008-5472.CAN-03-0875 PubMedCrossRef

32.

Monteleone I, Rizzo A, Sarra M, Sica G, Sileri P, Biancone L, MacDonald TT, Pallone F, Monteleone G (2011) Aryl hydrocarbon receptor-induced signals up-regulate IL-22 production and inhibit inflammation in the gastrointestinal tract. Gastroenterology 141(1):237–248, 248 e231. doi:10.1053/j.gastro.2011.04.007 PubMedCrossRef

33.

Monteleone I, Pallone F, Monteleone G (2013) Aryl hydrocarbon receptor and colitis. Semin Immunopathol 35(6):671–675. doi:10.1007/s00281-013-0396-2 PubMedCrossRef

34.

Sibilano R, Frossi B, Calvaruso M, Danelli L, Betto E, Dall’Agnese A, Tripodo C, Colombo MP, Pucillo CE, Gri G (2012) The aryl hydrocarbon receptor modulates acute and late mast cell responses. J Immunol 189(1):120–127. doi:10.4049/jimmunol.1200009 PubMedCrossRef

35.

Theoharides TC, Kempuraj D, Tagen M, Conti P, Kalogeromitros D (2007) Differential release of mast cell mediators and the pathogenesis of inflammation. Immunol Rev 217:65–78. doi:10.1111/j.1600-065X.2007.00519.x PubMedCrossRef

36.

Jutel M, Watanabe T, Klunker S, Akdis M, Thomet OA, Malolepszy J, Zak-Nejmark T, Koga R, Kobayashi T, Blaser K, Akdis CA (2001) Histamine regulates T-cell and antibody responses by differential expression of H1 and H2 receptors. Nature 413(6854):420–425. doi:10.1038/35096564 PubMedCrossRef

37.

Elenkov IJ, Webster E, Papanicolaou DA, Fleisher TA, Chrousos GP, Wilder RL (1998) Histamine potently suppresses human IL-12 and stimulates IL-10 production via H2 receptors. J Immunol 161(5):2586–2593PubMed

38.

Morgan RK, McAllister B, Cross L, Green DS, Kornfeld H, Center DM, Cruikshank WW (2007) Histamine 4 receptor activation induces recruitment of FoxP3+ T cells and inhibits allergic asthma in a murine model. J Immunol 178(12):8081–8089PubMedCrossRef

39.

Seifert R, Strasser A, Schneider EH, Neumann D, Dove S, Buschauer A (2013) Molecular and cellular analysis of human histamine receptor subtypes. Trends Pharmacol Sci 34(1):33–58. doi:10.1016/j.tips.2012.11.001 PubMedCrossRef

40.

Medina VA, Rivera ES (2010) Histamine receptors and cancer pharmacology. Br J Pharmacol 161(4):755–767. doi:10.1111/j.1476-5381.2010.00961.x PubMedPubMedCentralCrossRef

41.

Gri G, Piconese S, Frossi B, Manfroi V, Merluzzi S, Tripodo C, Viola A, Odom S, Rivera J, Colombo MP, Pucillo CE (2008) CD4 + CD25+ regulatory T cells suppress mast cell degranulation and allergic responses through OX40-OX40L interaction. Immunity 29(5):771–781. doi:10.1016/j.immuni.2008.08.018 PubMedPubMedCentralCrossRef

42.

Piconese S, Gri G, Tripodo C, Musio S, Gorzanelli A, Frossi B, Pedotti R, Pucillo CE, Colombo MP (2009) Mast cells counteract regulatory T-cell suppression through interleukin-6 and OX40/OX40L axis toward Th17-cell differentiation. Blood 114(13):2639–2648. doi:10.1182/blood-2009-05-220004 PubMedCrossRef

43.

Souza HS, Elia CC, Spencer J, MacDonald TT (1999) Expression of lymphocyte-endothelial receptor-ligand pairs, alpha4beta7/MAdCAM-1 and OX40/OX40 ligand in the colon and jejunum of patients with inflammatory bowel disease. Gut 45(6):856–863PubMedPubMedCentralCrossRef

44.

Malmstrom V, Shipton D, Singh B, Al-Shamkhani A, Puklavec MJ, Barclay AN, Powrie F (2001) CD134L expression on dendritic cells in the mesenteric lymph nodes drives colitis in T cell-restored SCID mice. J Immunol 166(11):6972–6981PubMedCrossRef

45.

de Vries VC, Wasiuk A, Bennett KA, Benson MJ, Elgueta R, Waldschmidt TJ, Noelle RJ (2009) Mast cell degranulation breaks peripheral tolerance. Am J Transplant 9(10):2270–2280. doi:10.1111/j.1600-6143.2009.02755.x PubMedCrossRef

46.

Grimbaldeston MA, Chen CC, Piliponsky AM, Tsai M, Tam SY, Galli SJ (2005) Mast cell-deficient W-sash c-kit mutant Kit W-sh/W-sh mice as a model for investigating mast cell biology in vivo. Am J Pathol 167(3):835–848. doi:10.1016/S0002-9440(10)62055-X PubMedPubMedCentralCrossRef

47.

Colombo MP, Piconese S (2009) Polyps wrap mast cells and Treg within tumorigenic tentacles. Cancer Res 69(14):5619–5622. doi:10.1158/0008-5472.CAN-09-1351 PubMedCrossRef

48.

Gounaris E, Erdman SE, Restaino C, Gurish MF, Friend DS, Gounari F, Lee DM, Zhang G, Glickman JN, Shin K, Rao VP, Poutahidis T, Weissleder R, McNagny KM, Khazaie K (2007) Mast cells are an essential hematopoietic component for polyp development. Proc Natl Acad Sci U S A 104(50):19977–19982. doi:10.1073/pnas.0704620104 PubMedPubMedCentralCrossRef

49.

Gounaris E, Blatner NR, Dennis K, Magnusson F, Gurish MF, Strom TB, Beckhove P, Gounari F, Khazaie K (2009) T-regulatory cells shift from a protective anti-inflammatory to a cancer-promoting proinflammatory phenotype in polyposis. Cancer Res 69(13):5490–5497. doi:10.1158/0008-5472.CAN-09-0304 PubMedPubMedCentralCrossRef

50.

Dennis KL, Wang Y, Blatner NR, Wang S, Saadalla A, Trudeau E, Roers A, Weaver CT, Lee JJ, Gilbert JA, Chang EB, Khazaie K (2013) Adenomatous polyps are driven by microbe-instigated focal inflammation and are controlled by IL-10-producing T cells. Cancer Res 73(19):5905–5913. doi:10.1158/0008-5472.CAN-13-1511 PubMedPubMedCentralCrossRef

51.

Cheon EC, Khazaie K, Khan MW, Strouch MJ, Krantz SB, Phillips J, Blatner NR, Hix LM, Zhang M, Dennis KL, Salabat MR, Heiferman M, Grippo PJ, Munshi HG, Gounaris E, Bentrem DJ (2011) Mast cell 5-lipoxygenase activity promotes intestinal polyposis in APCDelta468 mice. Cancer Res 71(5):1627–1636. doi:10.1158/0008-5472.CAN-10-1923 PubMedCrossRef

52.

Saleem SJ, Martin RK, Morales JK, Sturgill JL, Gibb DR, Graham L, Bear HD, Manjili MH, Ryan JJ, Conrad DH (2012) Cutting edge: mast cells critically augment myeloid-derived suppressor cell activity. J Immunol 189(2):511–515. doi:10.4049/jimmunol.1200647 PubMedPubMedCentralCrossRef

53.

Mandruzzato S, Solito S, Falisi E, Francescato S, Chiarion-Sileni V, Mocellin S, Zanon A, Rossi CR, Nitti D, Bronte V, Zanovello P (2009) IL4Ralpha + myeloid-derived suppressor cell expansion in cancer patients. J Immunol 182(10):6562–6568. doi:10.4049/jimmunol.0803831 PubMedCrossRef

54.

Yang Z, Zhang B, Li D, Lv M, Huang C, Shen GX, Huang B (2010) Mast cells mobilize myeloid-derived suppressor cells and Treg cells in tumor microenvironment via IL-17 pathway in murine hepatocarcinoma model. PLoS One 5(1):e8922. doi:10.1371/journal.pone.0008922 PubMedPubMedCentralCrossRef

55.

Molin D, Edstrom A, Glimelius I, Glimelius B, Nilsson G, Sundstrom C, Enblad G (2002) Mast cell infiltration correlates with poor prognosis in Hodgkin’s lymphoma. Br J Haematol 119(1):122–124PubMedCrossRef

56.

Franco G, Guarnotta C, Frossi B, Piccaluga PP, Boveri E, Gulino A, Fuligni F, Rigoni A, Porcasi R, Buffa S, Betto E, Florena AM, Franco V, Iannitto E, Arcaini L, Pileri SA, Pucillo C, Colombo MP, Sangaletti S, Tripodo C (2014) Bone marrow stroma CD40 expression correlates with inflammatory mast cell infiltration and disease progression in splenic marginal zone lymphoma. Blood. doi:10.1182/blood-2013-04-497271 PubMed

57.

Hedstrom G, Berglund M, Molin D, Fischer M, Nilsson G, Thunberg U, Book M, Sundstrom C, Rosenquist R, Roos G, Erlanson M, Amini RM, Enblad G (2007) Mast cell infiltration is a favourable prognostic factor in diffuse large B-cell lymphoma. Br J Haematol 138(1):68–71. doi:10.1111/j.1365-2141.2007.06612.x PubMedCrossRef

58.

Tripodo C, Gri G, Piccaluga PP, Frossi B, Guarnotta C, Piconese S, Franco G, Vetri V, Pucillo CE, Florena AM, Colombo MP, Pileri SA (2010) Mast cells and Th17 cells contribute to the lymphoma-associated pro-inflammatory microenvironment of angioimmunoblastic T-cell lymphoma. Am J Pathol 177(2):792–802. doi:10.2353/ajpath.2010.091286 PubMedPubMedCentralCrossRef

59.

Rabenhorst A, Schlaak M, Heukamp LC, Forster A, Theurich S, von Bergwelt-Baildon M, Buttner R, Kurschat P, Mauch C, Roers A, Hartmann K (2012) Mast cells play a protumorigenic role in primary cutaneous lymphoma. Blood 120(10):2042–2054. doi:10.1182/blood-2012-03-415638 PubMedCrossRef

60.

Yang FC, Ingram DA, Chen S, Zhu Y, Yuan J, Li X, Yang X, Knowles S, Horn W, Li Y, Zhang S, Yang Y, Vakili ST, Yu M, Burns D, Robertson K, Hutchins G, Parada LF, Clapp DW (2008) Nf1-dependent tumors require a microenvironment containing Nf1+/-- and c-kit-dependent bone marrow. Cell 135(3):437–448. doi:10.1016/j.cell.2008.08.041 PubMedPubMedCentralCrossRef

61.

Baratelli F, Le M, Gershman GB, French SW (2014) Do mast cells play a pathogenetic role in neurofibromatosis type 1 and ulcerative colitis? Exp Mol Pathol 96(2):230–234. doi:10.1016/j.yexmp.2014.02.006 PubMedCrossRef

62.

Eaden J (2004) Review article: colorectal carcinoma and inflammatory bowel disease. Aliment Pharmacol Ther 20(Suppl 4):24–30. doi:10.1111/j.1365-2036.2004.02046.x PubMedCrossRef

63.

Heijmans J, Buller NV, Muncan V, van den Brink GR (2012) Role of mast cells in colorectal cancer development, the jury is still out. Biochim Biophys Acta 1822(1):9–13. doi:10.1016/j.bbadis.2010.12.001 PubMedCrossRef

64.

Chichlowski M, Westwood GS, Abraham SN, Hale LP (2010) Role of mast cells in inflammatory bowel disease and inflammation-associated colorectal neoplasia in IL-10-deficient mice. PLoS One 5(8):e12220. doi:10.1371/journal.pone.0012220 PubMedPubMedCentralCrossRef

65.

Khan MW, Keshavarzian A, Gounaris E, Melson JE, Cheon EC, Blatner NR, Chen ZE, Tsai FN, Lee G, Ryu H, Barrett TA, Bentrem DJ, Beckhove P, Khazaie K (2013) PI3K/AKT signaling is essential for communication between tissue-infiltrating mast cells, macrophages, and epithelial cells in colitis-induced cancer. Clin Cancer Res 19(9):2342–2354. doi:10.1158/1078-0432.CCR-12-2623 PubMedPubMedCentralCrossRef

66.

Kim YJ, Hong KS, Chung JW, Kim JH, Hahm KB (2010) Prevention of colitis-associated carcinogenesis with infliximab. Cancer Prev Res (Phila) 3(10):1314–1333. doi:10.1158/1940-6207.CAPR-09-0272 CrossRef

67.

Gulubova M, Vlaykova T (2009) Prognostic significance of mast cell number and microvascular density for the survival of patients with primary colorectal cancer. J Gastroenterol Hepatol 24(7):1265–1275. doi:10.1111/j.1440-1746.2007.05009.x PubMedCrossRef

68.

Malfettone A, Silvestris N, Saponaro C, Ranieri G, Russo A, Caruso S, Popescu O, Simone G, Paradiso A, Mangia A (2013) High density of tryptase-positive mast cells in human colorectal cancer: a poor prognostic factor related to protease-activated receptor 2 expression. J Cell Mol Med 17(8):1025–1037. doi:10.1111/jcmm.12073 PubMedPubMedCentralCrossRef

69.

Frossi B, Gri G, Tripodo C, Pucillo C (2010) Exploring a regulatory role for mast cells: ‘MCregs’? Trends Immunol 31(3):97–102. doi:10.1016/j.it.2009.12.007 PubMedCrossRef

70.

Schmidt DR, Kao WJ (2007) The interrelated role of fibronectin and interleukin-1 in biomaterial-modulated macrophage function. Biomaterials 28(3):371–382. doi:10.1016/j.biomaterials.2006.08.041 PubMedCrossRef

71.

Junttila MR, de Sauvage FJ (2013) Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 501(7467):346–354. doi:10.1038/nature12626 PubMedCrossRef

72.

Lilla JN, Werb Z (2010) Mast cells contribute to the stromal microenvironment in mammary gland branching morphogenesis. Dev Biol 337(1):124–133. doi:10.1016/j.ydbio.2009.10.021 PubMedPubMedCentralCrossRef

73.

Yoshii M, Jikuhara A, Mori S, Iwagaki H, Takahashi HK, Nishibori M, Tanaka N (2005) Mast cell tryptase stimulates DLD-1 carcinoma through prostaglandin- and MAP kinase-dependent manners. J Pharmacol Sci 98(4):450–458PubMedCrossRef

74.

Abdel-Majid RM, Marshall JS (2004) Prostaglandin E2 induces degranulation-independent production of vascular endothelial growth factor by human mast cells. J Immunol 172(2):1227–1236PubMedCrossRef

75.

Coussens LM, Raymond WW, Bergers G, Laig-Webster M, Behrendtsen O, Werb Z, Caughey GH, Hanahan D (1999) Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev 13(11):1382–1397PubMedPubMedCentralCrossRef

76.

Harvima IT, Levi-Schaffer F, Draber P, Friedman S, Polakovicova I, Gibbs BF, Blank U, Nilsson G, Maurer M (2014) Molecular targets on mast cells and basophils for novel therapies. J Allergy Clin Immunol. doi:10.1016/j.jaci.2014.03.007 PubMed

77.

Caughey GH (2007) Mast cell tryptases and chymases in inflammation and host defense. Immunol Rev 217:141–154. doi:10.1111/j.1600-065X.2007.00509.x PubMedPubMedCentralCrossRef

78.

Coussens LM, Shapiro SD, Soloway PD, Werb Z (2001) Models for gain-of-function and loss-of-function of MMPs. Transgenic and gene targeted mice. Methods Mol Biol 151:149–179PubMed

79.

Shi ZG, Li JP, Shi LL, Li X (2012) An updated patent therapeutic agents targeting MMPs. Recent Pat Anticancer Drug Discov 7(1):74–101PubMedCrossRef

80.

Oka T, Kalesnikoff J, Starkl P, Tsai M, Galli SJ (2012) Evidence questioning cromolyn’s effectiveness and selectivity as a ‘mast cell stabilizer’ in mice. Lab Invest 92(10):1472–1482. doi:10.1038/labinvest.2012.116 PubMedPubMedCentralCrossRef

81.

Soucek L, Lawlor ER, Soto D, Shchors K, Swigart LB, Evan GI (2007) Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat Med 13(10):1211–1218. doi:10.1038/nm1649 PubMedCrossRef

82.

Pierotti MA, Tamborini E, Negri T, Pricl S, Pilotti S (2011) Targeted therapy in GIST: in silico modeling for prediction of resistance. Nat Rev Clin Oncol 8(3):161–170. doi:10.1038/nrclinonc.2011.3 PubMedCrossRef

83.

Ribatti D, Crivellato E (2011) Mast cells and tumors: from biology to clinic. In: Springer (ed) Mast cells and tumors: from biology to clinic.

84.

Pittoni P, Piconese S, Tripodo C, Colombo MP (2011) Tumor-intrinsic and -extrinsic roles of c-Kit: mast cells as the primary off-target of tyrosine kinase inhibitors. Oncogene 30(7):757–769. doi:10.1038/onc.2010.494 PubMedCrossRef

85.

Rajput AB, Turbin DA, Cheang MC, Voduc DK, Leung S, Gelmon KA, Gilks CB, Huntsman DG (2008) Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases. Breast Cancer Res Treat 107(2):249–257. doi:10.1007/s10549-007-9546-3 PubMedPubMedCentralCrossRef

86.

Wang B, Li L, Liao Y, Li J, Yu X, Zhang Y, Xu J, Rao H, Chen S, Zhang L, Zheng L (2013) Mast cells expressing interleukin 17 in the muscularis propria predict a favorable prognosis in esophageal squamous cell carcinoma. Cancer Immunol Immunother: CII 62(10):1575–1585. doi:10.1007/s00262-013-1460-4 PubMedCrossRef

87.

Fakhrjou A, Niroumand-Oscoei SM, Somi MH, Ghojazadeh M, Naghashi S, Samankan S (2013) Prognostic Value of Tumor-Infiltrating Mast Cells in Outcome of Patients with Esophagus Squamous Cell Carcinoma. J Gastrointest Cancer. doi:10.1007/s12029-013-9550-2

88.

Ammendola M, Sacco R, Donato G, Zuccala V, Russo E, Luposella M, Vescio G, Rizzuto A, Patruno R, De Sarro G, Montemurro S, Sammarco G, Ranieri G (2013) Mast cell positivity to tryptase correlates with metastatic lymph nodes in gastrointestinal cancer patients treated surgically. Oncology 85(2):111–116. doi:10.1159/000351145 PubMedCrossRef

89.

Chen L, Zhang Q, Chang W, Du Y, Zhang H, Cao G (2012) Viral and host inflammation-related factors that can predict the prognosis of hepatocellular carcinoma. Eur J Cancer 48(13):1977–1987. doi:10.1016/j.ejca.2012.01.015 PubMedCrossRef

90.

Welsh TJ, Green RH, Richardson D, Waller DA, O’Byrne KJ, Bradding P (2005) Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. J Clin Oncol 23(35):8959–8967. doi:10.1200/JCO.2005.01.4910 PubMedCrossRef

91.

Imada A, Shijubo N, Kojima H, Abe S (2000) Mast cells correlate with angiogenesis and poor outcome in stage I lung adenocarcinoma. Eur Respir J 15(6):1087–1093PubMedCrossRef

92.

Takanami I, Takeuchi K, Naruke M (2000) Mast cell density is associated with angiogenesis and poor prognosis in pulmonary adenocarcinoma. Cancer 88(12):2686–2692PubMedCrossRef

93.

Duncan LM, Richards LA, Mihm MC Jr (1998) Increased mast cell density in invasive melanoma. J Cutan Pathol 25(1):11–15PubMedCrossRef

94.

Ribatti D, Ennas MG, Vacca A, Ferreli F, Nico B, Orru S, Sirigu P (2003) Tumor vascularity and tryptase-positive mast cells correlate with a poor prognosis in melanoma. Eur J Clin Investig 33(5):420–425CrossRef

95.

Esposito I, Menicagli M, Funel N, Bergmann F, Boggi U, Mosca F, Bevilacqua G, Campani D (2004) Inflammatory cells contribute to the generation of an angiogenic phenotype in pancreatic ductal adenocarcinoma. J Clin Pathol 57(6):630–636PubMedPubMedCentralCrossRef

96.

Strouch MJ, Cheon EC, Salabat MR, Krantz SB, Gounaris E, Melstrom LG, Dangi-Garimella S, Wang E, Munshi HG, Khazaie K, Bentrem DJ (2010) Crosstalk between mast cells and pancreatic cancer cells contributes to pancreatic tumor progression. Clin Cancer Res 16(8):2257–2265. doi:10.1158/1078-0432.CCR-09-1230 PubMedPubMedCentralCrossRef

97.

Cai SW, Yang SZ, Gao J, Pan K, Chen JY, Wang YL, Wei LX, Dong JH (2011) Prognostic significance of mast cell count following curative resection for pancreatic ductal adenocarcinoma. Surgery 149(4):576–584. doi:10.1016/j.surg.2010.10.009 PubMedCrossRef

98.

Johansson A, Rudolfsson S, Hammarsten P, Halin S, Pietras K, Jones J, Stattin P, Egevad L, Granfors T, Wikstrom P, Bergh A (2010) Mast cells are novel independent prognostic markers in prostate cancer and represent a target for therapy. Am J Pathol 177(2):1031–1041. doi:10.2353/ajpath.2010.100070 PubMedPubMedCentralCrossRef

Titel: The Role of Mast Cells in Molding the Tumor Microenvironment
verfasst von: A. Rigoni
M. P. Colombo
C. Pucillo
Publikationsdatum: 01.12.2015
Verlag: Springer Netherlands
Erschienen in: Cancer Microenvironment / Ausgabe 3/2015
Print ISSN: 1875-2292
Elektronische ISSN: 1875-2284
DOI: https://doi.org/10.1007/s12307-014-0152-8

Springer Medizin

The Role of Mast Cells in Molding the Tumor Microenvironment

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2015

Stroma as an Active Player in the Development of the Tumor Microenvironment

Tumour Microenvironment: Overview with an Emphasis on the Colorectal Liver Metastasis Pathway

IL-1 in Colon Inflammation, Colon Carcinogenesis and Invasiveness of Colon Cancer

The Multifaceted Roles Neutrophils Play in the Tumor Microenvironment

Preface

Clinical Impact of Regulatory T cells (Treg) in Cancer and HIV

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie